A rare disease drug is rejected, even as the FDA talks about new approval pathway - statnews.com
Instead of approving Stealth BioTherapeutics' drug for Barth syndrome, the FDA withheld its endorsement, but decided it may be possible for Stealth to pursue accelerated approval.
Comments